Holen Sie sich die Stockscreener-App
0.8799
7.32%
0.06
Handel nachbörslich:
.87
-0.0099
-1.13%
Schlusskurs vom Vortag:
$0.8199
Offen:
$0.914901
24-Stunden-Volumen:
1.02M
Relative Volume:
0.16
Marktkapitalisierung:
$28.76M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-563.30K
KGV:
-4.4083
EPS:
-0.1996
Netto-Cashflow:
$-22.23M
1W Leistung:
+95.53%
1M Leistung:
+87.17%
6M Leistung:
-5.11%
1J Leistung:
-58.43%
1-Tages-Spanne:
$0.85
$0.92
1-Wochen-Bereich:
$0.411
$1.59
52-Wochen-Spanne:
$0.38
$2.095
Promis Neurosciences Inc Stock (PMN) Company Profile
Firmenname
Promis Neurosciences Inc
Sektor
Branche
Telefon
416-847-6898
Adresse
SUITE 200, 1920 YONGE STREET, TORONTO
Vergleichen Sie PMN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PMN
Promis Neurosciences Inc
|
0.8799 | 26.80M | 0 | -563.30K | -22.23M | -0.1996 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Promis Neurosciences Inc Aktie (PMN) Neueste Nachrichten
ProMIS Neurosciences Gains FDA Fast Track for PMN310 - The Globe and Mail
What analysts say about ProMIS Neurosciences Inc. stockExceptional market positioning - jammulinksnews.com
Is ProMIS Neurosciences Inc. a good long term investmentHigh-yield market plays - jammulinksnews.com
Earnings Misses And Clinical Hurdles Rattle Major Stocks - Finimize
Still undervalued? ProMIS Neurosciences keeps $9.50 target price at Leede - Cantech Letter
Alzheimer’s stock triples after FDA Fast-Track Designation - MSN
ProMIS Neurosciences Plunges 24.56% Intraday—Is the FDA Fast Track Outpacing Investor Sentiment? - AInvest
ProMIS Neurosciences Plunges 28% Intraday—Is This the Catalyst No One Saw Coming? - AInvest
What makes ProMIS Neurosciences Inc. stock price move sharplyBreakout Level Watch - Newser
Buy Rating for ProMIS Neurosciences Driven by Fast Track Designation and Promising Alzheimer’s Treatment Potential - TipRanks
ProMIS Neurosciences Announces Private Placement Financing - GlobeNewswire
What drives ProMIS Neurosciences Inc. stock priceFree Stock Index Interpretation - jammulinksnews.com
ProMIS Neurosciences announces $0.8M registered direct offering - TipRanks
ProMIS Neurosciences announces private placement financing - TipRanks
ProMIS Neurosciences stock gets FDA Fast Track designation for PMN310 - Investing.com
ProMIS Neurosciences (PMN) Secures Funding to Enhance Therapeuti - GuruFocus
ProMIS Neurosciences Announces $0.8 Million Registered Direct Offering, Priced At-the-Market Under Nasdaq Rules - The Manila Times
ProMIS Neurosciences Announces Private Placement Financing | PMN Stock News - GuruFocus
ProMIS Neurosciences Announces $2.4 Million PIPE Financing for Clinical Development of PMN310 - Nasdaq
ProMIS Neurosciences Drops 9.82% Amid ICICI Bank's Strong Earnings - AInvest
ProMIS Secures $9.2M Funding Boost: Accelerates Novel Alzheimer's Treatment Development - Stock Titan
Alzheimer's Treatment Pioneer ProMIS Secures New Funding to Accelerate PMN310 Clinical Trials - Stock Titan
ProMIS Neurosciences ends at-the-market agreement and receives FDA fast track for PMN310 - Investing.com Australia
3 Penny Stocks to Watch Now, 7/22/25 - TipRanks
ProMIS Neurosciences Inc. Stock Analysis and ForecastFree AI-Backed Trading Signals - jammulinksnews.com
ProMIS Neurosciences Inc Inc. (PMN) Price Performance: The Role of Supply and Demand - investchronicle.com
ProMIS Neurosciences shares surge 149.77% intraday after FDA grants Fast Track designation to PMN310 for Alzheimer’s treatment. - AInvest
Shares Of Micro Cap Biotech Surge After Breakthrough FDA Designation - The Globe and Mail
Alzheimer’s stock triples after FDA Fast-Track Designation | 2025-07-21 | Investing News - Stockhouse
ProMIS Neurosciences Soars 134%—What’s Fueling This Biotech Breakout? - AInvest
ProMIS Neurosciences (PMN) up more than 300% since Jul 8 - AInvest
Promis Neurosciences shares surge 250% intraday after FDA grants Fast Track designation for PMN310 Alzheimer's treatment. - AInvest
ProMIS Neurosciences: Stock Surge Insight - StocksToTrade
ProMIS Neurosciences Soars 157% on FDA Fast Track Designation – What’s Fueling This Volatile Rally? - AInvest
ProMIS Neurosciences Surges: Analyzing Recent Moves - timothysykes.com
ProMIS Neurosciences shares surge 21.37% premarket after FDA grants Fast Track designation to PMN310 for Alzheimer’s treatment. - AInvest
ProMIS Neurosciences stock price surges in pre market trading as company receives FDA fast track designation for alzheimer’s drug candidate PMN310 - MSN
Why Is ProMIS Neurosciences Stock (PMN) Up 180% Today? - TipRanks
ProMIS Neurosciences shares surge 17.50% premarket after FDA grants Fast Track designation to PMN310 for Alzheimer’s treatment. - AInvest
ProMIS Neurosciences stock soars after FDA grants Fast Track for Alzheimer’s drug - Investing.com India
Why ProMIS Is Rising In Pre-market? - Nasdaq
FDA grants fast track designation to ProMIS Neurosciences’ Alzheimer’s drug By Investing.com - Investing.com South Africa
FDA grants fast track designation to ProMIS Neurosciences’ Alzheimer’s drug - Investing.com Australia
ProMIS Neurosciences granted Fast Track designation by FDA for PMN310 - TipRanks
ProMIS Neurosciences Granted Fast Track Designation by U.S. - GlobeNewswire
FDA Fast-Tracks Revolutionary Alzheimer's Drug Promising Fewer Side Effects Than Current Treatments - Stock Titan
Finanzdaten der Promis Neurosciences Inc-Aktie (PMN)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.91%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):